Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.
Harding
Matthew W
MW
Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001692:Biological Transport; D002986:Clinical Trials as Topic; D006801:Humans; D020104:Immunophilins / Q000502:physiology*; D008954:Models, Biological; D008957:Models, Genetic; D017510:Protein Folding; D020033:Protein Isoforms; D011494:Protein Kinases / Q000502:physiology*; D017434:Protein Structure, Tertiary; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism; D015398:Signal Transduction; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases
D000903:Antibiotics, Antineoplastic; D020033:Protein Isoforms; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; D020104:Immunophilins; D020123:Sirolimus